Key result
Coronary slow flow is associated with significantly lower serum cystatin C levels versus CAD controls.
Why the study?
The association between serum cystatin C levels and coronary slow flow phenomenon in patients undergoing coronary angiography was unclear.
Are serum cystatin C levels associated with coronary slow flow in patients undergoing coronary angiography?
Observational (n=210)
Are serum cystatin C levels associated with coronary slow flow in patients undergoing coronary angiography?
p-value: p=<.001
Lower serum cystatin C levels are associated with coronary slow flow and correlate with the number of involved vessels and TIMI frame count.
May inform microvascular assessment; hypothesis-generating and should not yet change practice.
We assessed the association between serum cystatin C (CysC) levels and coronary slow flow (CSF) phenomenon in patients who underwent coronary angiography. A total of 210 patients (mean age 55.6 ± 10.9 years; 100 females) were included. Patients were divided into 3 groups, (patients with CSF [group 2], with coronary artery disease [CAD; group 3], and without CAD [group 1]). Serum CysC levels in patients with CSF were significantly lower than those with and without CAD (912.5 ± 135.6, 820.4 ± 104.2, and 1343.4 ± 236.6 ng/mL in groups 1, 2, and 3, respectively; P < .001). Serum CysC levels correlated with the number of vessels with CSF and mean corrected thrombolysis in myocardial infarction frame count (Spearman correlation coefficient [r s] = .192, P < .001 and r s = .261, P < .001 respectively). In conclusion, patients with CSF have lower CysC levels; this could be a useful biomarker of CSF involvement in patients who undergo diagnostic coronary angiography.
No takes yet. Share an insight, caveat, or question.
Taşal et al. (2013) conducted an observational in Coronary slow flow (n=210). Coronary slow flow vs. Patients with coronary artery disease and without coronary artery disease was evaluated on Serum cystatin C levels (p=<.001). Serum cystatin C levels were significantly lower in patients with coronary slow flow (820.4 ng/mL) compared to those without CAD (912.5 ng/mL) and with CAD (1343.4 ng/mL) (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: